MSK Vaccine to be Available in Multicenter Trials within 2020

It seems that YmAbs announced FDA pre-approval for the MSK Vaccine, in order to be applied to patients who achieve remission for relapse prevention:

Dr. Claus Moller, Chief Executive Officer further notes, “We are committed to bringing GD2-GD3 Vaccine to children with neuroblastoma, a life-threatening cancer with a clear unmet medical need. We are very pleased with the designation granted by the FDA, and plan to start a multicenter Phase II trial in neuroblastoma in 2020.”

Anybody knows further details about this? Will the clinical trials be available only in the US, or also in Europe/other continents?

4 Likes

Getting the Rare Pediatric Disease Designation is a big step forward. We will all no doubt stay tuned!

2 Likes